Skip to main content

Table 7 Supportive therapy

From: Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

 

Number of patients (%)

Cycle 1 (intravenously)

DD/DI arm (N = 86)

HDI arm (N = 80)

Paracetamol

79

(92)

71

(89)

Anti-emetics

47

(55)

44

(55)

Anti-diarrhea

3

(3)

2

(2)

Anti-anxiety

20

(23)

15

(19)

Vitamin

22

(26)

15

(19)

Subsequent cycles

DD/DI arm (N = 71)

HDI arm (N = 69)

Paracetamol

64

(90)

55

(80)

Anti-emetics

44

(62)

21

(30)

Anti-diarrhea

6

(8)

2

(3)

Anti-anxiety

19

(27)

16

(23)

Vitamin

21

(30)

18

(26)